Dianthus Therapeutics is a clinical-stage biotechnology company focused on next-generation complement therapeutics for severe autoimmune and inflammatory diseases. It became the combined public company after the 2023 reverse merger with former Dianthus, while continuing the former Dianthus operating business.
Dianthus Therapeutics will host a conference call on March 9, 2026, to discuss interim responder analysis results from Part A of the Phase 3 CAPTIVATE trial of claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
Korsana Biosciences launched from stealth with $175 million in funding to advance KRSA-028, a monoclonal antibody targeting amyloid beta plaques in Alzheimer's disease using a blood-brain barrier shuttle technology.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06858579 |
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE) |
RECRUITING | PHASE3 |
| NCT06537999 |
A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy |
RECRUITING | PHASE2 |
| NCT06282159 |
A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC) |
ACTIVE_NOT_RECRUITING | PHASE2 |
